A Study of Neoantigen mRNA Personalised Cancer in Patients With Advanced Solid Tumors

Personalized Neoantigen Peptide Vaccines for Solid Tumors

NCT07002203 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

A Study of Personalized Neoantigen Cancer Vaccines

NCT03794128 ·Status: COMPLETED

A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma

NCT01970358 ·Status: COMPLETED ·Phase: PHASE1

QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

NCT03169764 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2

Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer

NCT03480152 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.

NCT04881045 ·Status: COMPLETED ·Phase: PHASE1

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

NCT03526835 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors

NCT05159388 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Expanded Access To Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors

NCT06963697 ·Status: AVAILABLE

A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors

NCT03970382 ·Status: SUSPENDED ·Phase: PHASE1

Safety Study of a Liposomal Vaccine to Treat Malignant Melanoma

NCT01052142 ·Status: COMPLETED ·Phase: PHASE1

Development of Immunological Assays for the Evaluation of Tumor Antigen Specific Immunity

NCT02016833 ·Status: COMPLETED

Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

NCT00085189 ·Status: COMPLETED ·Phase: PHASE2

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

NCT05269381 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Solid Tumors

NCT06577532 ·Status: RECRUITING ·Phase: EARLY_PHASE1

Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma

NCT02673333 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors

NCT06635785 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread

NCT02737475 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Vaccine Therapy for Patients With Stage IV Melanoma

NCT00052156 ·Status: UNKNOWN ·Phase: PHASE3

Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy

NCT02432963 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.

NCT02598960 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Personalized Vaccine for Cancer Immunotherapy

NCT04879888 ·Status: COMPLETED ·Phase: PHASE1

QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors

NCT03169738 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

NCT07078604 ·Status: RECRUITING ·Phase: PHASE2

A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)

NCT07030712 ·Status: RECRUITING ·Phase: PHASE1